EDTUTC-4 New YorkLog in Sign up

CLDX
Celldex Therapeutics, Inc
stockNASDAQ

At CloseOct 28, 2026 3:59:57 PM EDT

29.66USD-1.642%(-0.49)899,158

Pre-marketOct 28, 2026 9:02:30 AM EDT

30.06USD-0.299%(-0.09)

After-hoursOct 28, 2026 4:46:30 PM EDT

29.24USD-1.397%(-0.41)

CLDX News

Day breaks

09:10 AM EDTSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX) ·

PR Newswire

05:48 PM EDTCelldex Therapeutics Leads Guggenheim’s Biotechnology Rankings ·

Investing.com

07:06 AM EDTMorgan Stanley raises Celldex Therapeutics price target on urticaria drug progress ·

Investing.com

02:17 AM EDTMarket Movers | Winners: VKTX, INDP, MAZE | Losers: XNDU, EVER, CLDX ·

Trefis

03:19 PM EDTCelldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria Transcript ·

Seeking Alpha

01:32 PM EDTWhy is Celldex Therapeutics stock sliding today? ·

Investing.com

11:31 AM EDTCelldex shares slip 15% as safety concerns cloud skin drug trial win ·

The Economic Times

11:06 AM EDTStifel reiterates Celldex Therapeutics stock Buy rating after trial data ·

Investing.com

08:36 AM EDTCelldex falls after late-stage trial data for hives therapy ·

Seeking Alpha

08:12 AM EDTWhy is Celldex Therapeutics stock plummeting today? ·

Investing.com

06:58 AM EDTCelldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints ·

GlobeNewswire Inc.